Lorenzo Gaetani

List of Publications by Year
in descending order

45 papers	1,951 citations	394421 19 h-index	276875 41 g-index
46 all docs	46 docs citations	46 times ranked	3126 citing authors

#	Article	IF	Citations
1	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	1.9	623
2	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	10.2	393
3	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	6.2	111
4	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3848-3857.	7.1	58
5	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 2020, 41, 1023-1037.	8.7	48
6	Î±-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies. Neurology, 2022, 99, 195-205.	1.1	45
7	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	3.6	41
8	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	6.4	38
9	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	3.6	35
10	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 157.	4.8	35
11	Neuroinflammation and Alzheimerâ€™s Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	4.1	34
12	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. Journal of Neuroimmunology, 2020, 339, 577108.	2.3	31
13	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Brain Research, 2015, 1621, 205-213.	2.2	30
14	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 2022, 37, 669-683.	3.9	30
15	The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimerâ€™s Disease, Parkinsonâ€™s Disease and Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 4958.	4.1	28
16	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology, 2012, 79, 1182-1184.	1.1	27
17	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. Neurobiology of Disease, 2018, 113, 97-108.	4.4	27
18	The Challenge of Disease-Modifying Therapies in Parkinsonâ€™s Disease: Role of CSF Biomarkers. Biomolecules, 2020, 10, 335.	4.0	25

#	Article	IF	Citations
19	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. Neural Regeneration Research, 2021, 16, 36.	3.0	23
20	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	2.0	20
21	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. Journal of Neuroinflammation, 2021, 18, 259.	7.2	20
22	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	19
23	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140537.	2.3	19
24	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. Frontiers in Neuroscience, 2021, 15, 672954.	2.8	19
25	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. European Journal of Neurology, 2014, 21, 648-653.	3.3	17
26	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 647783.	2.8	17
27	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. International Journal of Molecular Sciences, 2021, 22, 4440.	4.1	17
28	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. International Journal of Molecular Sciences, 2021, 22, 9753.	4.1	17
29	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. Amino Acids, 2021, 53, 435-449.	2.7	14
30	Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature. Journal of Neurology, 2016, 263, 422-427.	3.6	12
31	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences, 2017, 379, 236-240.	0.6	12
32	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	3.3	12
33	Serum neurofilament light chain as a preclinical marker of neurodegeneration. Lancet Neurology, The, 2019, 18, 1070-1071.	10.2	9
34	Infliximab monotherapy for neuro-Behçet's disease: A case report. Journal of the Neurological Sciences, 2014, 347, 389-390.	0.6	8
35	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. Journal of Neurology, 2022, 269, 3129-3135.	3.6	6
36	NfL as Analogue of C-Reactive Protein in Neurologic Diseases. Neurology, 2022, 98, 911-912.	1.1	6

#	Article	IF	Citations
37	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. Multiple Sclerosis and Related Disorders, 2017, 17, 217-219.	2.0	5
38	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. Journal of Neurology, 2018, 265, 522-529.	3.6	5
39	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. European Neurology, 2016, 76, 62-68.	1.4	4
40	Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. Neural Regeneration Research, 2019, 14, 77.	3.0	4
41	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. Journal of Neurology, 2016, 263, 1449-1451.	3.6	2
42	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. Clinica Chimica Acta, 2020, 506, 55-66.	1.1	2
43	A blood test for Alzheimer's disease: a step forward. Lancet Neurology, The, 2021, 20, 691-693.	10.2	1
44	Blood biomarkers may distinguish among dementia disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 571-571.	1.9	1
45	Phosphatidylethanolamine Binding Protein‑1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	1